the fy16 defense appropriations act provides $20 million (m) to the department of defense gulf war illness research program (gwirp) to support innovative, high-impact gulf war illness research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency, research, development, and acquisition (dha rda) directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

fy16 gwirp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

http://cdmrp.army.mil/funding/gwirp.shtml

gulf war illness epidemiology research award

independent investigators at all academic levels (or equivalent)

·         pre-application is required; full application submission is by invitation only.

·         supports population-based research to obtain a better understanding of mortality, morbidity, and symptomatology over time in veterans with gulf war illness (gwi).

·         additional topics of interest include clinical diagnoses and laboratory findings, symptom clustering and subgrouping, and gender and racial differences.

·         supports hypothesis-driven or discovery-based research.

• intervention clinical trials are not allowed.

·         maximum funding of $975,000 for direct costs (plus indirect costs)

• maximum period of performance is 3 years

new investigator award

transitioning postdoctoral fellow: senior postdoctoral fellows who have completed at least 3 years of postdoctoral training.

early-career investigator: independent investigators within 5 years since their last training position.

new gwi researcher: established independent investigators who have received less than $300,000 in federally funded, non-mentored gwi research funding.)

·         pre-application (letter of intent) is required.

·         encourages applications from investigators in the early stages of their careers and from established investigators new to the field of gwi research.

·         previous experience in gwi research is not required; however, collaborations with experienced gwi researchers are encouraged.

·         preliminary data are not required, and if provided, do not necessarily have to come from the gwi research field.

·         studies that provide outcomes clearly translatable to clinical use are encouraged.

• intervention clinical trials are not allowed.

·         maximum funding of $500,000 for direct costs (plus indirect costs)

• maximum period of performance is 3 years

clinical partnership award (new for fy15!)

independent investigators at all academic levels (or equivalent)

·         pre-application is required; full application submission is by invitation only.

·         supports translational research partnerships between clinicians and laboratory scientists to accelerate the movement of promising research hypotheses into clinical applications for gulf war illness

·         minimum of 2 pis required; maximum of 3 pis allowed

·         at least one partner must be a laboratory scientist and at least one partner must be a clinician

·         at least one partner must have significant experience in gulf war illness research

·         preliminary and/or published data are required that may be from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge from providing care to veterans.

• limited clinical testing is permissible but does not support definitive intervention clinical trials

·         maximum funding of $750,000 for direct costs (plus indirect costs)

• maximum period of performance is 3 years

investigator-initiated focused research award (new for fy15!)

independent investigators at all academic levels (or equivalent)

·         pre-application is required; full application submission is by invitation only.

·         supports research from idea generation through preclinical development for submission of applications to the fda under three tiers:

o   discovery tier:  supports basic research and proof of concept research, preliminary data is not required

o   development tier:  supports applied research in gwi aimed at diagnosis or therapeutic development. preliminary data from the field of gulf war illness (gwi) is required

o   validation tier:  supports the validation and optimization of promising leads in gwi treatment.  proposed studies are expected to be product-driven and result in the preclinical development of pharmacological agents up to ind submission

• does not support definitive clinical trials, but limited clinical testing is permissible

·         maximum period of performance is 2 years

·         maximum for direct cost  varies by tier:

o   discovery tier:
$200,000 (plus indirect costs)

o   development tier:
$600,000 (plus indirect costs)

• validation tier:
  $600,000 (plus indirect costs)

treatment evaluation award (new for fy15!)

independent investigators at all academic levels (or equivalent)

·         pre-application is required; full application submission is by invitation only.

·         supports small-scale, phase 0, i, i/ii clinical trial evaluations of treatments for gwi under two tracks:

o   data-based track:  evaluation of therapeutic approaches supported by significant preliminary data in gwi models or based on biological alterations identified in veterans with gwi.  preliminary data are required.

o   symptom-based treatment track:  evaluation of innovative approaches that may have been utilized for other chronic illnesses, but not yet studied in veterans with gwi.  preliminary data are not required.

• partnerships with the biotechnology or pharmaceutical industry are encouraged.

·         maximum funding of $700,000 for direct costs (plus indirect costs)

• maximum period of performance is 3 years

a pre-application is required and must be submitted through the cdmrp electronic biomedical research application portal (ebrap) (https://ebrap.org) prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all usamrmc funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

applications must be submitted through the federal government's single-entry portal, grants.gov.  for email notification when program announcements are released, go to the cdmrp website (http://cdmrp.army.mil) and select subscribe to funding opportunities & program communications.  for more information about the gwirp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507

the fy16 defense appropriations act provides $6 million (m) to the department of defense tuberous sclerosis complexresearch program (tscrp) to support innovative, high-impact tsc research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency, research, development, and acquisition (dha rda) directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

fy16 tscrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

focus areas:  the goal of the fy16 tscrp is to encourage innovative research aimed at understanding the pathogenesis, and preventing and treating the manifestations of tsc.  within this context, the fy16 tscrp encourages applications that address the critical needs of the tsc community in one or more of the following fy16 focus areas:

• understanding phenotypic heterogeneity in tsc
• gaining a deeper knowledge of tsc signaling pathways and the cellular consequences of tsc deficiency
• improving tsc disease models
• developing clinical biomarkers for tsc
• facilitating therapeutics and clinical trials research

http://cdmrp.army.mil/tscrp/default.shtml

exploration – hypothesis development award

investigators at all academic levels (or equivalent), including postdoctoral fellows.

supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the tsc research field.

projects involving human subjects or human biological substances must be exempt under 32 cfr 219.101(b)(4) or eligible for expedited review under 32 cfr 219.110 or 21 cfr 56.110.

preliminary data is not required.

research projects must be innovative, feasible, and supported by a strong rationale.

clinical trials not allowed.

maximum funding of $200,000 for direct costs (plus indirect costs).

maximum period of performance is 2 years.

idea development award

established investigators:

independent investigators with a documented faculty appointment (or equivalent);  or

new investigators:  

investigators who are early in their faculty appointments or in the process of developing independent research careers.

supports ideas that have the potential to yield high-impact findings and new avenues of investigation.

preliminary data is expected.

clinical trials not allowed.

new investigator option supports applicants who early in their faculty appointments or in the process of developing independent research careers.

applications from new investigators and established investigators will be peer- and programmatically reviewed separately.

maximum funding of $450,000 for direct costs (plus indirect costs).

maximum period of performance is 3 years

pilot clinical trial award

must be an independent investigator at or above the level of assistant professor (or equivalent).

supports exploratory studies with limited human exposure that produce diagnostic or therapeutic information, toxicity studies of an intervention, and studies to determine the mechanism of action and side effects of an intervention.

aims at collecting preliminary data to support the rationale and design of subsequent clinical trial(s).

preliminary or preclinical data is required

maximum funding of $300,000 for direct costs (plus indirect costs).

maximum period of performance is 2 years.

postdoctoral training award

must have successfully defended a doctoral thesis or possess an m.d. degree.

supports tsc research training opportunities for postdoctoral trainees who are recent doctoral graduates.

pis must have a designated mentor who is an experienced tsc researcher.

maximum funding of $150,000 for direct costs (plus indirect costs).

maximum period of performance is 3 years.

synergistic idea development award

each pi must be an independent investigator at or above the level of assistant professor (or equivalent).

supports new or existing partnerships between two or three independent investigators, who should utilize their complementary and synergistic perspectives to address a central innovative question or problem in tsc.

pis are expected to demonstrate within the application the synergistic components (i.e., leveraging disciplines, expertise, or critical resources) that will significantly advance the project such that the research outcomes as a whole will be realized rapidly and efficiently and could not otherwise be accomplished through independent efforts of a single pi.

each partner will be recognized as a pi, and a separate award will be made to each pi, even if the pis are at the same organization.

preliminary data is expected.

clinical trials are not allowed.

maximum funding of $750,000 for direct costs (plus indirect costs)

maximum period of performance is 3 years.

a pre-application (letter of intent) is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions t available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released go to the cdmrp website (http://cdmrp.army.mil) and select subscribe to funding opportunities & program communications.  for more information about the tscrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507

help@ebrap.org

the canadian forces health services group (cfhsg) is seeking a leader in the field of mental health research related to canadian military personnel to convene and facilitate an expert panel to review cfhsg mental health (mh) programs and suicide prevention activities.  the objective of this work is to conduct a strategic level review of the various components of these programs and activities, and to consider the adequacy of these compared to current evidence informed best practices and the mental health needs of the caf.

the canadian institute for military and veteran health research (cimvhr) has entered into partnership with the government of canada to procure research and development services related to the mental, social and physical wellbeing of active military members, veterans and their families.  cimvhr is seeking notices of interest from qualified researchers to enter into a contract with cimvhr to produce this work.

the fy16 defense appropriations act provides $80 million (m) to the department of defense prostate cancer research program (pcrp) to support innovative, high-impact prostate cancer research. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency, research, development, and acquisition (dha rda) directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp). 

fy16 pcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

important:  the pcrp’s fy16 mission is to find and fund research that will lead to the elimination of death and enhance the well-being of men with prostate cancer.  as such, the pcrp seeks to focus applications and direct funding by providing four overarching challenges and seven focus areas to address critical needs in prostate cancer research and clinical management.  applicants are strongly encouraged to submit research that addresses one or more of the overarching challenges and focus areas.

overarching challenges:  (1) distinguish aggressive from indolent disease in men newly diagnosed with prostate cancer.  (2)develop strategies to prevent progression to lethal prostate cancer.  (3) develop effective treatments and address mechanisms of resistance for men with high-risk or metastatic prostate cancer.  (4) develop strategies to optimize the physical and mental health of men with prostate cancer.

focus areas:  (1) biomarker development.  (2) genetics.  (3) imaging.  (4) mechanisms of resistance and response.  (5) survivorship and palliative care.  (6) therapy.  (7) tumor and microenvironment biology.

clinical consortium research site award

independent investigators at or above the level of assistant professor (or equivalent)

·      supports the addition of a clinical research site to the prostate cancer clinical trials consortium.

o  this consortium facilitates the rapid execution of collaborative phase ii or phase i/ii clinical trials that will bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease the impact of prostate cancer.

·      funds may not be used for research or development of clinical protocols.

·      sites must provide plans for accruing patients from populations disproportionately affected by prostate cancer.

·      trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer are encouraged.

·     maximum funding of $600k for direct costs (plus indirect costs)

·     maximum period of performance is 3 years

impact award

independent investigators at or above the level of assistant professor (or equivalent)

·      preproposal is required; application submission is by invitation only.

·      supports high-impact, potentially high-risk, studies (including clinical trials) that address a central question or problem in prostate cancer.  as such, the primary emphasis of this mechanism is on impact.

·      potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.

·      proposed projects may include basic, translational, or clinical research, including clinical trials.

·      preliminary data to support feasibility are required.

partnering pi option:

·      provides a higher level of funding to support synergistic partnerships between two or three independent investigators collaborating on a single application.

·      pis are expected to demonstrate within the application the synergistic components that will significantly advance the project such that the research outcomes could not otherwise be accomplished through independent efforts of a single pi.

·         allows for individual awards to multiple sites (maximum of three sites in total), provided the combined direct costs for all sites does not exceed the $2m maximum.

individual pis:

·     maximum funding of $750k for direct costs (plus indirect costs)

·     maximum period of performance is 3 years

partnering pi option:

·     maximum funding of $2m for direct costs (plus indirect costs)

·     maximum period of performance is 3 years

health disparity research award

established investigators:  independent investigators at or above the level of assistant professor (or equivalent); or

new investigators:  investigators that meet the following criteria at the application submission deadline date:

·    have the freedom to pursue individual aims without formal mentorship

·    have not previously received a pcrp health disparity research award

·    have either completed at least 3 years of postdoctoral training or fellowship or are within 5 years of having begun first independent faculty position (or equivalent)

·      preproposal is required; application submission is by invitation only.

·      supports new ideas for prostate cancer research that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality. 

·      preliminary data are encouraged but not required.

·      new investigator option supports applicants early in their faculty appointments or in the process of developing independent research careers.

·      qualified collaborator option supports a higher level of funding for pis who include a collaborator that significantly contributes (10% level of effort or greater and provides both intellectual input and research resources) to the research project such that it could not otherwise be accomplished.

·      nested health disparity (hd) traineeship option supports predoctoral and postdoctoral training, nested within the overall proposed project, for individuals committed to pursuing careers as independent investigators in prostate cancer health disparity research.

·     maximum funding of $450k for direct costs (plus indirect costs)

·     if applying for the qualified collaborator option, maximum funding of $600k for direct costs (plus indirect costs)

·     maximum period of performance is 3 years

·     additional funds can be requested if including the nested hd traineeship option

idea development award

established investigators:  independent investigators at or above the level of assistant professor (or equivalent); or

new investigators:  investigators that meet the following criteria at the application submission deadline date:

·    have the freedom to pursue individual aims without formal mentorship

·    have not previously received a pcrp idea development award

·    have either completed at least 3 years of postdoctoral training or fellowship or are within 5 years of having begun first independent faculty position (or equivalent)

·      preproposal is required; application submission is by invitation only.

·      supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research, and have the potential to make an important contribution to eliminating death and enhancing the well-being of men with prostate cancer.

·      emphasis is equally placed on innovation and impact.

·      preliminary data are encouraged but not required.

·      clinical trials are not allowed.

·      new investigator option supports applicants early in their faculty appointments or in the process of developing independent research careers.

·      partnering pi option:

o  provides a higher level of funding to support synergistic partnerships between two or three independent established investigators collaborating on a single application.

o  pis are expected to demonstrate within the application the synergistic components that will significantly advance the project such that the research outcomes could not otherwise be accomplished through independent efforts of a single pi.

o  allows for individual awards to multiple sites (maximum of three sites in total), provided the combined direct costs for all sites does not exceed the $1m maximum.

established pis:

·     maximum funding of $600k for direct costs (plus indirect costs)

new investigator option:

·     maximum funding of $275k for direct costs (plus indirect costs)

partnering pi option:

·     maximum funding of $1m for direct costs (plus indirect costs)

·     maximum period of performance is 3 years

physician research award

at the time of application submission, the pi must be either:

·       in the last year of an accredited medical residency or medical fellowship program;

or

within 3 years of having initiated an appointment as instructor, assistant professor, or equivalent

·      supports mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.

·      pis must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.

·      pis must have a designated mentor with an established research program in prostate cancer.

·      institutions must provide at least 40% protection of pi’s time for research.

·      projects that focus on basic research are highly encouraged.

·     maximum funding of $130k per year for direct costs (plus indirect costs)

·     maximum period of performance is 4 years

prostate cancer early investigator research award

by march 31, 2017,

predoctoral ph.d. and m.d./ph.d. pis:

·    must be enrolled full-time in an accredited doctoral program and must have completed all predissertation requirements

postdoctoral ph.d. or m.d. pis:

·    must have successfully defended a doctoral thesis or possess an m.d. degree, and

·    have 3 years or less of postdoctoral fellowship

·      supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.

·      pis must have a designated mentor who is an experienced prostate cancer researcher.

predoctoral ph.d. and m.d./ph.d. pis:

·     maximum funding of $60k for direct costs (plus indirect costs)

·     period of performance cannot exceed 2 years

postdoctoral m.d. or ph.d. pis:

·     maximum of $125k for direct costs (plus indirect costs)

·     period of performance cannot exceed 2 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  requests for email notification of the program announcements release may be sent to help@cdmrp.org.  for more information about the pcrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507

help@ebrap.org

the fiscal year 2016 (fy16) defense appropriations act provides $278.7 million to the department of defense peer reviewed medical research program (prmrp).  the vision of the prmrp is to improve the health and well-being of all military service members, veterans, and beneficiaries.  the prmrp challenges the scientific and clinical communities to address one of the fy16 congressionally directed topic areas with original ideas that foster new directions in basic science and translational research; novel product development leading to improved therapeutic or diagnostic tools; synergistic, multidisciplinary research programs; or clinical trials that address an immediate clinical need.

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency, research, development and acquisition (dha rda) directorate manages the defense health program (dhp) research, development, test and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

fy16 prmrp program announcements and general application instructions are posted on grants.gov.

congressionally directed topic areas.  the fy16 prmrp will solicit research applications for the following 39 topics areas:

 *         acute lung injury
*         antimicrobial resistance
*         chronic migraine and post-traumatic headache
*         congenital heart disease
*         constrictive bronchiolitis
*         diabetes
*         dystonia
*         emerging infectious diseases
*         focal segmental glomerulosclerosis
*         fragile x syndrome
*         hepatitis b
*         hereditary angioedema
*         hydrocephalus
*         inflammatory bowel disease
*         influenza
*         integrative medicine
*         interstitial cystitis
*         lupus
*         malaria
*         metals toxicology
*         mitochondrial disease
*         nanomaterials for bone regeneration
*         nonopioid pain management
*         pancreatitis
*         pathogen-inactivated dried plasma
*         polycystic kidney disease
*         post-traumatic osteoarthritis
*         psychotropic medications
*         pulmonary fibrosis
*         respiratory health
*         rett syndrome
*         rheumatoid arthritis
*         scleroderma
*         sleep disorders
*         tinnitus
*         tuberculosis
*         vaccine development for infectious disease
*         vascular malformations
*         women's heart disease

military relevance:  relevance to the healthcare needs of the military service members, veterans, and beneficiaries is a key feature of each fy16 prmrp award mechanism.

clinical trial award
*       assistant professor level or above (or equivalent)
*       supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.
*       proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
*       investigational new drug or investigational device exemption applications, if needed, should be submitted to the food and drug administration before the prmrp grants.gov application submission deadline.
*       preproposal submission is required; application submission is by invitation only
*       funding limit not defined; requested funding must be appropriate for the scope of work proposed
*       maximum period of performance is 5 years

discovery award
*       all investigators
*       supports the exploration of a highly innovative new concept or untested theory.
*       not intended to support the logical progression of an already established line of questioning.
*       clinical trials will not be funded.
*       reviewers will be blinded to the identity of the principal investigator (pi), collaborators, and their organization(s)
*       maximum of $200,000 for direct costs (plus indirect costs)
*       maximum period of performance is 18 months

focused program award
*       full professor level or above (or equivalent)

*       supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal in one of the topic areas listed directly above. projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications. projects may range from exploratory/ hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question. research team of highly qualified, multidisciplinary project leaders should be led by a pi with demonstrated success in directing large, focused projects.
*       preproposal submission is required; application submission is by invitation only.
*       maximum of $10 million for total costs (includes direct and indirect costs)
*       maximum period of performance is 5 years

investigator-initiated research award
*       assistant professor level or above (or equivalent)
*       supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.
*       partnering pi option available.
*       clinical trials will not be funded.
*       preproposal submission is required; application submission is by invitation only.
*       maximum of $1.2 million for direct costs (plus indirect costs)
*       maximum of $1.5 million for direct costs (plus indirect costs) for applications including a partnering pi option
*       maximum period of performance is 3 years

technology/ therapeutic development award
assistant professor level or above (or equivalent)
*       supports the development of diagnostics or therapies that have the potential to make a strong impact on patient care in the topic area(s) of interest.
*       product-oriented (e.g., device, drug, clinical guidelines).
*       clinical trials will not be funded.
*       preproposal submission is required; application submission is by invitation only
*       maximum of $3.0 million for direct costs (plus indirect costs)
*       maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org <https://ebrap.org>prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov <http://www.grants.gov/>

sshrc is proud to mark canada’s 150th anniversary in 2017. all across the country and in a variety of ways, canadians will be celebrating this historic occasion. we believe this anniversary is an opportunity to acknowledge and support scholarly or research-related activities which mobilize research about canada at 150: its past, its present and its future.

many milestones—social, political, cultural, economic—helped shape canada as we know it today, and they continue to influence our leaders and impact our citizens from one generation to the next. understanding these milestones, and their consequences, is the domain of the social sciences and humanities.

it is in that spirit that sshrc is pleased to offer connecting for canada’s 150th, a unique series of connection grants to support one hundred and fiftieth anniversary-related initiatives organized by postsecondary institutions and scholars. these events or outreach activities should mark or celebrate this historic anniversary, enhancing our understanding of the social, cultural, technological, environmental and economic issues we face at 150.

this funding opportunity also provides support for connection activities which exemplify the contributions of canadian institutions and researchers in social sciences and humanities, either to a discipline or to global fields of study. 

application process:

to be considered for funding under the connecting for canada’s 150th initiative, applicants must complete the application form and follow the accompanying instructions, as outlined in the connection grant funding opportunity description.

sshrc will accept applications for this initiative for one of the following deadlines:

• august 1, 2016;
• november 1, 2016; and
• february 1, 2017.

established in 2012, the canadian safety and security program (cssp) is a federally-funded program that enhances canada's public safety and security through investments in science and technology (s&t). more specifically, the cssp strengthens canada’s ability to anticipate, prevent, mitigate, prepare for, respond to and recover from natural disasters, serious accidents, crime and terrorism through the convergence of s&t with policy, operations and intelligence.  the ccsp is is led by defence research and development canada’s centre for security science (drdc css), in partnership with public safety canada.

defence research and development canada’s centre for security science activities address a broad range of public safety and security domains that cross multiple areas of s&t interest, which are not limited to the presentation included in this guidebook. the areas of s&t research include:
 critical infrastructure resilience
o critical infrastructure
o e-security
 seamless border
o border security
o transportation security
o surveillance, intelligence and interdiction
 threats and hazards mitigation
o chemical
o biological
o radiological-nuclear
o explosives
o natural hazards
 safer communities
o emergency management systems and interoperability
o communications interoperability
o wireless technologies
o fire services
o paramedic services
o police and law enforcement
o psycho-social wellbeing

the types of projects that will be considered for funding are:
 studies;
 research and development;
 technology demonstrations; and
 technology pilots.

the responsive grants program enables the law foundation of ontario to fund ideas generated by non-profit community groups to improve access to justice. these grants have provided seed funding for hundreds of innovative projects across ontario.

objectives

the purpose of this funding opportunity is to award supplementary support to sshrc-funded researchers who have received a sshrc grant in the past six years in areas related to immigration and refugee resettlement. it is intended to:

• support researchers addressing pressing, short-term research issues related to the current refugee resettlement effort;
• support research and related activities that may inform the efforts of policy-makers, service organizations and other stakeholders;
• support targeted and policy-relevant research focused on the syrian refugee population, in areas such as employment, social integration, children and youth, resilience, trauma, (re)settlement surveys and mental health; and
• engage interested canadian researchers and teams to mobilize knowledge and provide findings that may inform government policy and foster stakeholder engagement.